These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11772334)

  • 21. Oxcarbazepine for refractory epilepsy: systematic review of the literature.
    Saconato H; Prado GF; Puga ME; Atallah AN
    Sao Paulo Med J; 2009; 127(3):150-9. PubMed ID: 19820875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice.
    Pauletto G; Bergonzi P;
    Seizure; 2006 Apr; 15(3):150-5. PubMed ID: 16439165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
    Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
    Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxcarbazepine add-on for drug-resistant partial epilepsy.
    Castillo S; Schmidt DB; White S
    Cochrane Database Syst Rev; 2000; (3):CD002028. PubMed ID: 10908522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.
    Friis ML; Kristensen O; Boas J; Dalby M; Deth SH; Gram L; Mikkelsen M; Pedersen B; Sabers A; Worm-Petersen J
    Acta Neurol Scand; 1993 Mar; 87(3):224-7. PubMed ID: 8475694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine.
    Dickinson RG; Hooper WD; Pendlebury SC; Moses D; Eadie MJ
    Clin Exp Neurol; 1988; 25():127-33. PubMed ID: 3077098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide.
    Leppik IE
    J Child Neurol; 2002 Jan; 17 Suppl 1():S53-7. PubMed ID: 11918464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development outlook of oxcarbazepine.
    Schwabe S
    Epilepsia; 1994; 35 Suppl 3():S2-4. PubMed ID: 8156975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of efficacy of trileptal (oxcarbazepine) and carbamazepine in the treatment of temporal epilepsy].
    Sokolova LV; Kalinin VV; Zheleznova EV; Zemlianaia AA; Polianskiĭ DA; Basamygin AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; Suppl 2():63-7. PubMed ID: 19431253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
    Ambrósio AF; Soares-Da-Silva P; Carvalho CM; Carvalho AP
    Neurochem Res; 2002 Feb; 27(1-2):121-30. PubMed ID: 11926264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
    Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
    J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.
    Beydoun A; Sachdeo RC; Rosenfeld WE; Krauss GL; Sessler N; Mesenbrink P; Kramer L; D'Souza J
    Neurology; 2000 Jun; 54(12):2245-51. PubMed ID: 10881247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.
    Maschio M; Dinapoli L; Sperati F; Fabi A; Pace A; Vidiri A; Muti P
    J Neurooncol; 2012 Feb; 106(3):651-6. PubMed ID: 21847705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the efficacy and tolerability of oxcarbazepine oral suspension between infants and children with epilepsy: a retrospective chart review at a single medical center in Taiwan.
    Wei SH; Liu CC; Fan PC
    Paediatr Drugs; 2014 Feb; 16(1):83-9. PubMed ID: 24081427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
    Baruzzi A; Albani F; Riva R
    Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oxcarbazepine in the treatment of drug-resistant epilepsy in children and adolescents: preliminary study].
    Kluczyński A
    Neurol Neurochir Pol; 2000; 34 Suppl 1():215-20. PubMed ID: 10768161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis.
    Van Parys JA; Meinardi H
    Epilepsy Res; 1994 Sep; 19(1):79-85. PubMed ID: 7813417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oxcarbazepine in the treatment of epilepsy. A review and update].
    Horga de la Parte JF; Horga A
    Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
    Gaily E; Granström ML; Liukkonen E
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():41-5. PubMed ID: 10030431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.